EUDA: Powering digital asset adoption in wellness
A demographic wave is reshaping Asia: rapidly aging populations are set to drive multi-trillion-dollar demand for non-invasive, preventive, and longevity-focused healthcare. And one under-the-radar Singapore innovator may be building one of the region’s most comprehensive toolkits—from next-gen nutraceuticals and bioenergy therapies to stem-cell programs and emerging genetic-modulation technologies.
Now, EUDA is adding a new catalyst to this ecosystem: the QB utility token.
Rather than functioning as a simple rewards mechanism, the QB token transforms EUDA’s wellness network into a unified, digital-first engagement platform. Customers can earn and redeem QB across EUDA’s full suite of offerings—spanning Bioenergy Capsule sessions, EUDA Helixe supplements, and select stem-cell services—creating a closed-loop loyalty system that deepens retention and expands lifetime value.
By combining preventive healthcare with tokenized digital engagement, EUDA is positioning itself at the center of Asia’s longevity boom—where wellness, technology, and consumer incentives converge into a next-generation health ecosystem
Why the Market Set-Up Looks So
Compelling Right Now
Demographic Tailwind – By 2030, more than 550 million people in China and ASEAN will be over 60, driving a longevity market forecast to eclipse $2 trillion annually.
Regulatory Fast-Track – Singapore and Malaysia have introduced expedited pathways for wellness and cell-therapy products, shrinking go-to-market timelines.
Tech Convergence – Advances in CRISPR, stem-cell banking, and AI-driven diagnostics are converging, lowering costs and boosting efficacy—perfect timing for first movers.
EUDA Health Holdings Limited (EUDA)
Ticker / Exchange
EUDA / NASDAQ
Core Focus
Non-invasive, preventive longevity solutions
Headquarters
Singapore
Target Geography
Singapore, Malaysia, India and Mainland China
EUDA’s mission
is simple yet audacious
Transform the health and wellness landscape by leveraging cutting-edge technology to enhance non-invasive treatments and expand holistic healthcare access in Southeast Asia. The company offers a diverse portfolio of innovative non-invasive wellness products and services, including bioenergy capsules and stem cell therapies, marketed under the CK Health brand in Malaysia and Singapore.
EUDA Integrates QB Utility Token into Its Healthcare Ecosystem
EUDA’s integration of the QB utility token marks a major step toward building a unified digital health and rewards ecosystem, letting customers earn and redeem tokens across treatments, supplements, and longevity programs. By anchoring the platform on blockchain infrastructure and interoperability with USD1 stablecoins, EUDA is positioning itself at the forefront of transparent, compliant digital healthcare engagement. This creates a scalable foundation for cross-border wellness experiences that blend preventive care, tokenized incentives, and seamless digital access across Asia.
1
Tangible connection between crypto and product
The token integration is not a speculative crypto play; EUDA only receives QB tokens in exchange for products and services, keeping transactions non-monetary and reducing balance sheet exposure while still capturing ecosystem value.
2
Built for customer retention
The digital rewards architecture strengthens customer retention and lifetime value across high-margin wellness and longevity services, creating a scalable pathway for recurring revenues and cross-market expansion.
3
Partnership with QB issuer
Partnering with QB Limited allows EUDA to leverage an independently developed, purpose-built token and established distribution channels in Hong Kong and Macau, accelerating digital engagement without incurring full infrastructure, regulatory, or go-to-market costs.
Technological modernization without engaging in token issuance or speculation
This Integration Strengthens EUDA's Ecosystem By Enabling:
Greater user engagement through digital utilities
Enhanced transparency through on-chain verification
A compliant alternative to traditional rewards mechanisms
QB Will Increase Momentum Across EUDA's Four Flagship Growth Drivers
Euda Helixe Supplement
Euda Helixe is a next-generation immune health formula that modulates gene expression by activating beneficial genes while silencing harmful ones, leveraging cutting-edge epigenetic science. Management projects 500,000 bottles sold in the next 12 months, underscoring Euda Helixe’s potential as the cornerstone of EUDA’s precision-wellness portfolio.
EUDA Helixe 2.0 — EUDA’s flagship longevity nutraceutical has been reformulated with enhanced active ingredients and advanced delivery technology to improve potency, bioavailability, and global market appeal. With halal certification and optimized nutrient absorption, Helixe 2.0 is positioned to support cellular protection, skin health, metabolic resilience, and long-term vitality.
Euda Bioenergy Capsules
Positioned as a non-invasive, full-body wellness system that brings together six complementary technologies in a single 50-minute session, the Bioenergy Capsule is designed to boost vitality, immunity, and cellular recovery through integrated light, frequency, thermal, and magnetic therapies. EUDA’s CK Health subsidiary aims to deploy 1,000+ capsules across Southeast Asia in 2025, creating a regional network that can deliver over 1 million treatment sessions annually. This hardware-as-wellness model provides recurring revenue while funnelling users toward EUDA’s higher-margin supplements and therapies.
Stem-Cell Therapies & T-Cell Immunotherapy
Through commercial distribution agreements with Guangdong Cell Biotech, EUDA gains access to a repertoire of autologous stem-cell treatments already serviced by 37 treatment centers spanning China, Indonesia, and Cambodia. A subsequent deal with Shenzhen Inno Immune extends the portfolio to affordable T-cell immunotherapies retailing at USD8,000—a fraction of traditional costs—broadening their reach. These partnerships accelerate EUDA’s entry into regenerative medicine without heavy capex while positioning the company as a one-stop longevity platform.
In December 2025, EUDA launched a comprehensive stem cell therapy platform and opened its first longevity clinic in Shenzhen, China as part of accelerating its regenerative medicine strategy. EUDA also announced a nationwide stem cell extraction, processing, cryogenic storage, logistics, and clinical delivery platform in China with strategic partners Shenzhen Inno Immune and Wuhan Kaien Hospital.
CRISPR Gene Editing Platform
EUDA frames CRISPR not as another therapy but as a “genetic operating system” capable of precisely cutting out what no longer serves you and enhancing what does. The program targets aging-related genes to strengthen immunity, improve detox pathways, and mitigate inherited disease risks. By integrating CRISPR with its nutraceuticals and cell therapies, EUDA envisions a closed-loop longevity ecosystem—from molecular maintenance to cellular rejuvenation (stem cells) and finally DNA-level optimization (CRISPR)—unlocking multiple monetization tiers as regulatory frameworks evolve
Recent Milestones Building Real Momentum
EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask
Announced on 1 June 2026, EUDA Health Holdings Limited (NASDAQ: EUDA) disclosed the expansion of its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask ("Regenixé Mask"), a beauty product developed by Singapore-based biotech company Chemokine Pte Ltd. The Regenixé Mask is formulated with iPSC-derived skin stem cell secretome technology and cellulose mask technology designed to support skin hydration, brightening, and overall recovery, building on EUDA's exclusive global distributorship rights for Helixé products. EUDA views secretome-based skincare as a growing category within the premium beauty and wellness market, citing Mordor Intelligence forecasts that the global face mask market will grow from approximately US$7.95 billion in 2026 to around US$9.08 billion by 2031, with Asia-Pacific remaining one of the largest regions for facial masks and skincare products. To capitalise on this opportunity, EUDA intends to leverage its established distribution networks and regional wellness partnerships in Malaysia and China to drive sales of the Regenixé Mask and expand the broader Helixé product line across the Asia-Pacific region, supporting the Singapore-based provider's strategic pivot toward non-invasive, preventive, and longevity-focused wellness offerings.
EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency
Announced on 1 June 2026, EUDA Health Holdings Limited (NASDAQ: EUDA) disclosed that it has regained compliance with the Minimum Market Value of Listed Securities ("MVLS") requirement for continued listing on the Nasdaq Capital Market. The Company had previously received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market on 23 April 2026, indicating that it had failed to maintain the required MVLS of US$35 million over 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). On 28 May 2026, Nasdaq notified the Company that its Market Value of Listed Securities had remained at or above US$35 million for ten consecutive business days from 13 May to 27 May 2026, thereby satisfying the requirement and resolving the prior deficiency. With this matter now closed, EUDA has restored its standing for continued listing on the Nasdaq Capital Market as the Singapore-based provider continues to pursue its growth strategy in non-invasive, preventive, and longevity-focused healthcare across Singapore, Malaysia, and China.
EUDA isn’t just announcing bold ideas—it’s executing a roll-up strategy that will change the landscape for non-invasive healthcare across Southeast Asia.
Investment Thesis in One Sentence
Even a small foothold in Asia’s surging longevity market could dramatically revalue EUDA, especially as the QB-enabled digital rewards ecosystem deepens customer engagement and accelerates platform-wide growth.
Latest
News
01 JUN 2026
SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask (“Regenixé Mask”), a beauty product developed by Chemokine Pte Ltd (“Chemokine”).
Singapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).
SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of cellular therapies in China, has received official approval under the 2025 Shenzhen Key Industry R&D Program.
Seasoned Leadership Steering the Longevity Vision
EUDA’s executive bench blends decades of life-sciences expertise with hard-nosed operational know-how—an essential mix for scaling a multi-faceted wellness platform.
Chief Executive Officer
Alfred Lim
A 44-year veteran of cross-border trade, Lim launched his career in 1978 at European pharma heavyweight May & Baker/Rhône-Poulenc before leading Borealis Singapore through eight years of regional expansion. As EUDA’s CEO, he channels that deal-making pedigree into the company’s aggressive roll-up strategy while leveraging deep supplier relationships across ASEAN.
Interim Chief Financial Officer
Vivian Tay
Formerly a senior auditor with Big 4 experience, Tay implements rigorous capital-allocation discipline as EUDA juggles multiple M&A tracks and product launches. Her background in cross-border accounting standards ensures smooth regulatory filings on both NASDAQ and Singaporean fronts.
Managing Director, EUDA Health Malaysia
Johnson Tang
Johnson Tang is an engineering and technology veteran with over 30 years of experience in system integration, nanotechnology, renewable energy, and wellness technologies. He has extensive expertise in RFID systems, advanced technology commercialization, and BioEnergy Capsule Therapy Technology (BECT). As Managing Director of EUDA Health Malaysia, he oversees technical operations, business development, and strategic growth initiatives.
Operational Director
Aaron Lim
Mr. Lim has extensive experience in operational strategy. He drives efficiency, oversees critical processes and ensures seamless execution across the organization. Mr. Lim combines analytical precision with a proven track record of delivering results.
EUDA’s leadership combines deal velocity, scientific rigor, and financial discipline—the very attributes that can turn a diversified longevity toolkit into a dominant regional franchise.